Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma

Shota Tanaka, Fredric B. Meyer, Jan Craig Buckner, Joon H. Uhm, Elizabeth S. Yan, Ian F Parney

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Few studies have assessed the presentation, management, and outcome of anaplastic astrocytoma (AA) in elderly patients in the temozolomide era. We retrospectively reviewed 42 consecutive patients aged >65 years with newly-diagnosed AA who underwent surgical resection or biopsy between 2003 and 2008. Median age and KPS score were 73 years (range, 66-88) and 80 (range, 50-90), respectively. Thirty-two patients (76 %) presented with focal deficits. Twenty patients (48 %) experienced seizures before surgery. Tumor enhanced diffusely in 24 patients (57 %) and sparsely in 18 patients (43 %). Biopsy (79 %) was more common than resection. Post-operatively, new persistent neurological deficits and hemorrhage were seen in two (4.8 %) and three (7.1 %) patients, respectively. Complete follow-up data regarding adjuvant treatment was available in 31 patients. Sixteen patients (52 %) received temozolomide and radiation therapy (RT), while nine patients (29 %) received RT alone. Chemotherapy-related grade 3/4 hematologic complication rate was 17.6 %. Median overall survival (OS) was 6.5 months (12 months with resection; 3.5 months with biopsy). Resection (P = 0.007, risk ratio = 0.21) and sparse enhancement (P = 0.007, risk ratio = 0.13) were associated with longer OS in multivariate analysis. Similarly, chemoradiation was associated with longer survival compared to RT alone (OS: P = 0.01, progression-free survival (PFS): P = 0.02) after adjusting for age, KPS, enhancement, and surgery. Resection was associated with longer survival among elderly patients with AA, although this could reflect selection bias. Similarly, adding chemotherapy to RT was associated with prolonged survival but carried important complication risks. In appropriately selected AA patients, aggressive treatments with radical resection and chemoradiation may be appropriate even in this age group.

Original languageEnglish (US)
Pages (from-to)227-235
Number of pages9
JournalJournal of Neuro-Oncology
Volume110
Issue number2
DOIs
StatePublished - Nov 2012

Fingerprint

Astrocytoma
temozolomide
Survival
Radiotherapy
Biopsy
Odds Ratio
Drug Therapy
Selection Bias
Disease-Free Survival
Seizures
Multivariate Analysis
Age Groups
Hemorrhage

Keywords

  • Anaplastic astrocytoma
  • Chemotherapy
  • Elderly
  • Radiation therapy
  • Surgery

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology

Cite this

Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. / Tanaka, Shota; Meyer, Fredric B.; Buckner, Jan Craig; Uhm, Joon H.; Yan, Elizabeth S.; Parney, Ian F.

In: Journal of Neuro-Oncology, Vol. 110, No. 2, 11.2012, p. 227-235.

Research output: Contribution to journalArticle

Tanaka, Shota ; Meyer, Fredric B. ; Buckner, Jan Craig ; Uhm, Joon H. ; Yan, Elizabeth S. ; Parney, Ian F. / Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma. In: Journal of Neuro-Oncology. 2012 ; Vol. 110, No. 2. pp. 227-235.
@article{49d47353c8044a73bffa9f853af791a9,
title = "Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma",
abstract = "Few studies have assessed the presentation, management, and outcome of anaplastic astrocytoma (AA) in elderly patients in the temozolomide era. We retrospectively reviewed 42 consecutive patients aged >65 years with newly-diagnosed AA who underwent surgical resection or biopsy between 2003 and 2008. Median age and KPS score were 73 years (range, 66-88) and 80 (range, 50-90), respectively. Thirty-two patients (76 {\%}) presented with focal deficits. Twenty patients (48 {\%}) experienced seizures before surgery. Tumor enhanced diffusely in 24 patients (57 {\%}) and sparsely in 18 patients (43 {\%}). Biopsy (79 {\%}) was more common than resection. Post-operatively, new persistent neurological deficits and hemorrhage were seen in two (4.8 {\%}) and three (7.1 {\%}) patients, respectively. Complete follow-up data regarding adjuvant treatment was available in 31 patients. Sixteen patients (52 {\%}) received temozolomide and radiation therapy (RT), while nine patients (29 {\%}) received RT alone. Chemotherapy-related grade 3/4 hematologic complication rate was 17.6 {\%}. Median overall survival (OS) was 6.5 months (12 months with resection; 3.5 months with biopsy). Resection (P = 0.007, risk ratio = 0.21) and sparse enhancement (P = 0.007, risk ratio = 0.13) were associated with longer OS in multivariate analysis. Similarly, chemoradiation was associated with longer survival compared to RT alone (OS: P = 0.01, progression-free survival (PFS): P = 0.02) after adjusting for age, KPS, enhancement, and surgery. Resection was associated with longer survival among elderly patients with AA, although this could reflect selection bias. Similarly, adding chemotherapy to RT was associated with prolonged survival but carried important complication risks. In appropriately selected AA patients, aggressive treatments with radical resection and chemoradiation may be appropriate even in this age group.",
keywords = "Anaplastic astrocytoma, Chemotherapy, Elderly, Radiation therapy, Surgery",
author = "Shota Tanaka and Meyer, {Fredric B.} and Buckner, {Jan Craig} and Uhm, {Joon H.} and Yan, {Elizabeth S.} and Parney, {Ian F}",
year = "2012",
month = "11",
doi = "10.1007/s11060-012-0956-7",
language = "English (US)",
volume = "110",
pages = "227--235",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Presentation, management, and outcome of elderly patients with newly-diagnosed anaplastic astrocytoma

AU - Tanaka, Shota

AU - Meyer, Fredric B.

AU - Buckner, Jan Craig

AU - Uhm, Joon H.

AU - Yan, Elizabeth S.

AU - Parney, Ian F

PY - 2012/11

Y1 - 2012/11

N2 - Few studies have assessed the presentation, management, and outcome of anaplastic astrocytoma (AA) in elderly patients in the temozolomide era. We retrospectively reviewed 42 consecutive patients aged >65 years with newly-diagnosed AA who underwent surgical resection or biopsy between 2003 and 2008. Median age and KPS score were 73 years (range, 66-88) and 80 (range, 50-90), respectively. Thirty-two patients (76 %) presented with focal deficits. Twenty patients (48 %) experienced seizures before surgery. Tumor enhanced diffusely in 24 patients (57 %) and sparsely in 18 patients (43 %). Biopsy (79 %) was more common than resection. Post-operatively, new persistent neurological deficits and hemorrhage were seen in two (4.8 %) and three (7.1 %) patients, respectively. Complete follow-up data regarding adjuvant treatment was available in 31 patients. Sixteen patients (52 %) received temozolomide and radiation therapy (RT), while nine patients (29 %) received RT alone. Chemotherapy-related grade 3/4 hematologic complication rate was 17.6 %. Median overall survival (OS) was 6.5 months (12 months with resection; 3.5 months with biopsy). Resection (P = 0.007, risk ratio = 0.21) and sparse enhancement (P = 0.007, risk ratio = 0.13) were associated with longer OS in multivariate analysis. Similarly, chemoradiation was associated with longer survival compared to RT alone (OS: P = 0.01, progression-free survival (PFS): P = 0.02) after adjusting for age, KPS, enhancement, and surgery. Resection was associated with longer survival among elderly patients with AA, although this could reflect selection bias. Similarly, adding chemotherapy to RT was associated with prolonged survival but carried important complication risks. In appropriately selected AA patients, aggressive treatments with radical resection and chemoradiation may be appropriate even in this age group.

AB - Few studies have assessed the presentation, management, and outcome of anaplastic astrocytoma (AA) in elderly patients in the temozolomide era. We retrospectively reviewed 42 consecutive patients aged >65 years with newly-diagnosed AA who underwent surgical resection or biopsy between 2003 and 2008. Median age and KPS score were 73 years (range, 66-88) and 80 (range, 50-90), respectively. Thirty-two patients (76 %) presented with focal deficits. Twenty patients (48 %) experienced seizures before surgery. Tumor enhanced diffusely in 24 patients (57 %) and sparsely in 18 patients (43 %). Biopsy (79 %) was more common than resection. Post-operatively, new persistent neurological deficits and hemorrhage were seen in two (4.8 %) and three (7.1 %) patients, respectively. Complete follow-up data regarding adjuvant treatment was available in 31 patients. Sixteen patients (52 %) received temozolomide and radiation therapy (RT), while nine patients (29 %) received RT alone. Chemotherapy-related grade 3/4 hematologic complication rate was 17.6 %. Median overall survival (OS) was 6.5 months (12 months with resection; 3.5 months with biopsy). Resection (P = 0.007, risk ratio = 0.21) and sparse enhancement (P = 0.007, risk ratio = 0.13) were associated with longer OS in multivariate analysis. Similarly, chemoradiation was associated with longer survival compared to RT alone (OS: P = 0.01, progression-free survival (PFS): P = 0.02) after adjusting for age, KPS, enhancement, and surgery. Resection was associated with longer survival among elderly patients with AA, although this could reflect selection bias. Similarly, adding chemotherapy to RT was associated with prolonged survival but carried important complication risks. In appropriately selected AA patients, aggressive treatments with radical resection and chemoradiation may be appropriate even in this age group.

KW - Anaplastic astrocytoma

KW - Chemotherapy

KW - Elderly

KW - Radiation therapy

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84867872088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867872088&partnerID=8YFLogxK

U2 - 10.1007/s11060-012-0956-7

DO - 10.1007/s11060-012-0956-7

M3 - Article

C2 - 22875708

AN - SCOPUS:84867872088

VL - 110

SP - 227

EP - 235

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -